true

Products

Steripath^® Initial Specimen Diversion Device^®

Achieve sustained near-zero blood culture contamination rates ^1-6

Contact Now

Integrate the Steripath^® Initial Specimen Diversion Device^® (ISDD^®)in your blood culture protocol to achieve near-zero blood culture contamination rates.^1-6

A woman in a lab coat speaks on the phone

Despite best efforts, hospitals still face specimen contamination issues

Even when following best practice procedures for skin preparation, contamination can still occur since up to 20% of the skin flora remains viable in the keratin layer of the skin.⁷   

False positive results due to contamination and insufficient blood culture volume can carry numerous downstream consequences, such as misdiagnosis, unnecessary broad spectrum antibiotic treatment, delayed antibiotic de-escalation, prolonged time to accurate diagnosis, repeat diagnostic testing, increased length of stay, unnecessary costs, and added strain to health careinfrastructure.^8-10

A medium-wide shot of blood being drawn from the arm of a patient

A simple, all-in-one evidence-based solution

Steripath^® ISDD^® is an FDA 510(k)-cleared device specifically indicated to reduce blood culture contamination. It is backed by 9 studies, supporting sustained results of zero or near-zero blood culture contamination rates for both peripheral stick and fresh peripheral IV start blood culture draws.^1-6,11-13

By obtaining blood culture specimens free from contaminants, you can ensure that a positive is a true positive and be confident that the right antibiotic treatment decisions can be made as early as possible.

The needle is removed from the patient's arm and the puncture site is covered with gauze

A safe and streamlined workflow

Steripath^® ISDD^® utilizes the BD Vacutainer^® Push Button Blood Collection Set technology which enables single-handed, in vein activation that retracts the needle and can reduce accidental needlestick injuries by 88% as compared to manual safety wingsets.^14,15   

Learn more*

In addition, Steripath^® ISDD^® seamlessly integrates with BD BACTEC™ blood culture media and BD Vacutainer^® blood collection tubes for streamlined and efficient blood collection.

Create the opportunity to remove avoidable errors, variability and inefficiencies in blood culture collection.

By reducing false-positive blood cultures, Steripath^® can help  you achieve sustainable clinical and economical impact.

Hospital costs

Decrease annual hospital costs by an average of $1.9M for small to medium-sized U.S. hospitals.¹³
Patient outcomes

Shorten average length of stay by 2.2 days.^12,13
Antimicrobial stewardship

Achieve up to a 31% incremental reduction in vancomycin days of therapy.⁴

Bloodstream Infection Solution

Learn more

Our Partners

Magnolia Medical Technologies

Go to website*

Accelerate Diagnostics

Go to website*

*By clicking this link you are leaving bd.com and going to a third party website. Steripath^® is a registered trademark of Magnolia Medical Technologies. Pheno^® is a registered trademark of Accelerate Diagnostics.

BD Diagnostic Solutions is Now Waters Advanced Diagnostics

BD Diagnostic Solutions and Biosciences have combined with Waters Corporation to create a life sciences and diagnostics leader driven by innovation and a relentless commitment to our customers.

As we begin our new journey as part of Waters, there will be no immediate changes in how we serve you. The way you order your products and services and how you process payment for them will not change. Your points of contact for sales, customer service, technical service and support or clinical services will remain the same.

LEARN MORE

Get in touch with our sales representative

Bell M et al. J Emerg Nurs. 2018;44(6):570–5.
Arenas M et al. J Emerg Nurs. 2021;47(2):256–64.
Zimmerman FS et al. Am J Infect Control. 2019;47(7):822–6.
Nielsen LE et al. J Hosp Infect. 2021;120:127–33.
Povroznik MD. Am J Med Qual. 2022;37(5):405–12.
Tompkins LS et al. Infect Control Hosp Epidemiol. 2023;44(9):1386–90.
Anjanappa T, Arjun A. J Evid Based Med. 2015;2(2):131–54.
Doern GV et al. Clin Microbiol Rev. 2020;33(1):e00009–19.
CDC. Preventing Adult Blood Culture Contamination: A Quality Tool for Clinical Laboratory Professionals. Available at: https://www.cdc.gov/labquality/docs/BCC-Prevention_A-Quality-Tool_CDC.pdf. Accessed October 2023.
Lamy B et al. Front Microbiol. 2016;7:697.
Rupp ME et al. Clin Infect Dis. 2017;65(2):201–5.
Skoglund E et al. J Clin Microbiol. 2019;57(1):e01015-18.
Geisler BP et al. J Hosp Infect. 2019;102(4):438–44.
Dicristina DL. Successfully reducing wingset-related needlestick injuries: A combination of institutional culture, staff commitment and semi-passive safety device. AOHP. Spring 2014. https://www.bd.com/resource.aspx?IDX=31023.
Hotaling M. Jt Comm J Qual Patient Saf. 2009;35(2):100–5.
Mouser A et al. J Appl Lab Med. 2017;2(2):201–10.
Merrill VD et al. J Appl Lab Med. 2022;7(2):532–40.
Padoan A et al. Clin Chim Acta. 2020;500:213–9.
BD Synapsys™ Microbiology Informatics Solution User's Manual (L011216).
BD™ Bruker MALDI Biotyper CA System User Manual (8603291).
Saffert RT et al. J Clin Microbiol. 2011;49(3):887–92.
Knabl L et al. Lett Appl Microbiol. 2021;73(1):2–8.
Watanabe N et al. J Infect Chemother. 2022;28(4):563–8.
BD Phoenix™ M50 Automated Microbiology System User's Manual (500008930).
Carey RB et al. Failure of Automated Systems to Detect Vancomycin-Resistant Staphylococcus aureus. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, 2004.
Tenover FC et al. Emerg Infect Dis. 2006;12(8):1209–13.
Kulah C et al. BMC Infect Dis. 2009;9:30.
Mittman SA et al. J Clin Microbiol. 2009;47(11):3557–61.
Woodford N et al. J Clin Microbiol. 2010;48(8):2999–3002.

This business has been acquired by Waters Corporation (“Waters”). For products referenced on this page, the legal manufacturer remains Becton, Dickinson and Company or one of its affiliates or subsidiaries (“BD”) until all required regulatory transfers are completed. During this interim period, BD maintains full responsibility for all regulatory obligations of the legal manufacturer. Product information provided here is supplied under the regulatory authority of BD. To learn more about the relationship between Waters and BD during this transition period, please see our detailed summary waters.com/bdtransaction.